Renal denervation as therapy for hypertension: potentials and unanswered questions

Area of Science:

• Cardiology
• Interventional Cardiology
• Nephrology

Background:

• Cardiovascular diseases are a leading cause of death globally, with hypertension as a major risk factor.
• Many patients with hypertension do not achieve treatment goals with medication alone.
• Resistant hypertension poses a significant clinical challenge, necessitating novel therapeutic approaches.

Purpose of the Study:

• To evaluate the potential of percutaneous catheter-based renal denervation for uncontrolled and resistant hypertension.
• To assess the initial efficacy and safety of renal denervation in reducing blood pressure.
• To highlight the need for further research into the long-term outcomes and cost-effectiveness of this intervention.

Main Methods:

• A randomized trial was conducted to assess the effects of renal denervation.
• Blood pressure measurements were taken 6 months post-treatment.
• The study focused on patients with uncontrolled hypertension, including those with resistant hypertension.

Main Results:

• 84% of patients experienced a blood pressure reduction of at least 10 mmHg.
• 39% of patients achieved a systolic blood pressure of 140 mmHg or less.
• Short-term results indicate promising efficacy in lowering blood pressure.

Conclusions:

• Percutaneous renal denervation is a promising therapy for patients with resistant hypertension.
• Further international collaboration and randomized trials are essential to address safety, sustainability, cost-effectiveness, and cardiovascular event rates.
• The findings support the initiation of larger studies to fully understand the role of renal denervation in hypertension management.